Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novartis Pharma Services AG
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A study to evaluate clear skin effect in patients with plaque psoriasis
To assess the proportion of patients achieving a DLQI 0/1 response at Week 16 in 3 pre defined subpopulations and in the overall study population.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A combined phase 1 and 2 study investigating the combination of RAD001 and erlotinib in patients with advanced NSCLC previously treated only with chemotherapy
Overall, this study aims to assess the value of combined treatment with RAD001 and erlotinib in patients with advanced NSCLC previously treated only with hemotherapy as systemic therapy. The study con...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Ruxolitinib efficacy and safety in patients with HU resistant or intolerant polycythemia vera vs best available therapy
efficacy of ruxolitinib to BAT as assessed by Hct control at Week 28
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A study of the experimental drug BKM120 with paclitaxel in patients with HER2 negative, locally advanced or metastatic breast cancer, with or without PI3K activation
To assess the treatment effect of BKM120 once daily plus weekly paclitaxel versus BKM120 matching placebo once daily plus weekly paclitaxel on progression-free survival (PFS)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis účinnost a bezpečnost fingolimodu 0.5 mg u pacientů s primární progresivní roztroušenou sklerózou
To evaluate the effect of 0.5mg fingolimod relative to placebo on delaying the time to sustained disability progression.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A phase IV, long-term, open-label, multicenter extension study to evaluate the safety and tolerability of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)
This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of open-label ranibizumab administered to subjects with subfoveal choroidal neovasculari...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A randomized, open-label, parallel-group study to investigate blood concentrations, safety and tolerability of 2 ointment formulations of ASM981 in adult patients with atopic dermatitis treated topically for 2 weeks
•To evaluate the short-term safety and tolerability of 2 formulations of 1% pimecrolimus ointment when applied twice a day for 2 weeks on the lesional skin of patients with moderate to severe atopic d...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A clinical study with INC280 in combination with gefitinib in patients with non-small cell lung cancer
1) Phase Ib: To estimate the MTD or RP2D of INC280 in combination with gefitinib in NSCLC patients who have c-MET gene dysregulation 2) Phase II: To estimate overall clinical activity of INC280 in co...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
Safety and Efficacy of mometasone furoate delivered via Breezhaler® or Twisthaler® in adult and adolescent patients with persistent asthma
To demonstrate the non-inferiority of MF 80 µg and 320 µg delivered via Concept1 to MF 200 µg and 800 µg delivered via Twisthaler® in terms of 24 h post-dose trough FEV1 after 4 weeks treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novartis Pharma Services AG
MAJ Il y a 5 ans
A 26-week treatment, multi center, randomized, double blind, double dummy, placebo controlled, parallel group study to assess the efficacy and safety of indacaterol (150 μg o.d.) in patients with chronic obstructive pulmonary disease, using salmeterol (50 μg b.i.d.) as an active control
To assess indacaterol (150 μg) superiority in patients with COPD as compared to placebo with respect to 24 h post dose trough FEV1 after 12 weeks of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
19
20
21
22
23
24
25
26
27
28
Suivant